<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022876</url>
  </required_header>
  <id_info>
    <org_study_id>ALRN-6924-1-03</org_study_id>
    <nct_id>NCT04022876</nct_id>
  </id_info>
  <brief_title>A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)</brief_title>
  <official_title>A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aileron Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aileron Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of&#xD;
      chemotherapy-induced side effects.&#xD;
&#xD;
      Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of&#xD;
      chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line&#xD;
      treatment with topotecan. (Part 1 has completed enrollment).&#xD;
&#xD;
      Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of&#xD;
      ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with&#xD;
      p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with&#xD;
      carboplatin plus pemetrexed with or without immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During Part 1 SCLC, topotecan will be administered per standard practice on Days 1-5 of&#xD;
      21-day cycles. Patients will be randomized to receive 1 of 2 initial ALRN-6924 dose levels,&#xD;
      to be administered prior to each planned topotecan dose. The incidence, severity and duration&#xD;
      of hematologic toxicities, including neutropenia, thrombocytopenia, and febrile neutropenia,&#xD;
      will be determined. The safety and tolerability of each ALRN-6924 dose level will be assessed&#xD;
      during Part 1. ALRN-6924 is given either 24 hr or 6 hr prior to each topotecan&#xD;
      administration.&#xD;
&#xD;
      Part 2 NSCLC of the study will be conducted in two stages. In Stage 1, a total of 20 patients&#xD;
      will be randomized 1:1 to receive (with or without immunotherapy) either carboplatin plus&#xD;
      pemetrexed plus ALRN-6924 or carboplatin plus pemetrexed plus placebo.&#xD;
&#xD;
      During Stage 1 of Part 2 NSCLC, two interim analyses will be conducted after 10 and 20&#xD;
      patients, respectively, have been evaluated. The purpose of the two interim analyses is to&#xD;
      confirm safety and exclude futility. In Stage 2 of Part 2 NSCLC, an additional 40 patients&#xD;
      will be randomized to treatment as described for Stage 1.&#xD;
&#xD;
      Immunotherapy and/or bevacizumab may be used concurrently with chemotherapy and after&#xD;
      completion of 1st-line treatment (i.e., for maintenance purposes) as per local standard of&#xD;
      care. Time of administration of immunotherapy and/or bevacizumab relative to chemotherapy&#xD;
      will follow local standards of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b Part 2 NSCLC</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Proportion of completed treatment cycles that are free of Grade ≥ 3 hematological toxicities (including neutropenia, anemia, thrombocytopenia and febrile neutropenia), and free of chemotherapy dose reductions, and free of use of growth factors and transfusions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b Part 1 SCLC</measure>
    <time_frame>Approximately 19 months</time_frame>
    <description>Proportion of patients with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3/4 treatment emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SCLC: ALRN-6924+Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALRN-6924</intervention_name>
    <description>ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.</description>
    <arm_group_label>Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered IV on Day 1 of every 21-day cycle.</description>
    <arm_group_label>Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed</arm_group_label>
    <arm_group_label>Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed administered IV on Day 1 of every 21-day cycle.</description>
    <arm_group_label>Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed</arm_group_label>
    <arm_group_label>Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.</description>
    <arm_group_label>Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALRN-6924</intervention_name>
    <description>ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.</description>
    <arm_group_label>Part 1 SCLC: ALRN-6924+Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan administered IV on Days 1-5 of every 21-day cycle.</description>
    <arm_group_label>Part 1 SCLC: ALRN-6924+Topotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1b, Part 2 NSCLC Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology.&#xD;
             Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available&#xD;
             for p53 mutation analysis. FDA approved liquid biopsies are also acceptable.&#xD;
&#xD;
          -  Presence of one or more p53 mutations.&#xD;
&#xD;
          -  Measurable disease using RECIST 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.&#xD;
&#xD;
          -  Adequate hematological status.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
        Phase 1b, Part 2 NSCLC Exclusion Criteria:&#xD;
&#xD;
          -  Advanced NSCLC tumors with EGFR mutations or ALK re-arrangement or other actionable&#xD;
             genetic aberrations for which an approved targeted treatment is available. Patients&#xD;
             who received prior treatment with EGFR or ALK inhibitors or other systemic drugs or&#xD;
             immunotherapy for NSCLC are not eligible.&#xD;
&#xD;
          -  Patients who are candidates for anti-PD-1 monotherapy in 1st line advanced NSCLC (e.g.&#xD;
             tumors with high PD-L1 expression).&#xD;
&#xD;
          -  Presence of active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.&#xD;
&#xD;
        Phase 1b, Part 1 SCLC Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological confirmation of ED SCLC that has recurred or been refractory to one&#xD;
             line of treatment with standard platinum-based chemotherapy or immuno-chemotherapy.&#xD;
             Patients who received immunotherapy after platinum-based chemotherapy are eligible.&#xD;
&#xD;
          -  Presence of one or more p53 mutations.&#xD;
&#xD;
          -  Measurable disease using RECIST 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.&#xD;
&#xD;
          -  Adequate hematological status.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
        Phase 1b, Part 1 SCLC Exclusion Criteria:&#xD;
&#xD;
          -  More than one line of prior chemotherapy for ED SCLC (prior immunotherapy is&#xD;
             permitted, concurrent with or subsequent to first line chemotherapy).&#xD;
&#xD;
          -  Presence of active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Revive Research Institute Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adil Akhtar, MD</last_name>
      <phone>248-721-9539</phone>
      <email>aakhtar@rev-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savitha Balaraman, MD</last_name>
      <phone>248-564-1485</phone>
      <email>sbalaraman@rev-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Y Gabrail, MD</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>209</phone_ext>
      <email>ngabrailmd@gabrailcancercenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska, Lung Clinic</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirko Turic, MD</last_name>
      <phone>+387 51 343 289</phone>
      <email>mirko.turic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Clinic for Lung Disease</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bakir Mehic, MD</last_name>
      <phone>+387 33 297 825</phone>
      <email>bakir.mehic@kcus.ba</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Oncology Clinic</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timur Ceric, MD</last_name>
      <phone>+387 33 298 054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodryg Ramlau, MD</last_name>
      <phone>+48 616 561 700</phone>
      <email>rramlau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHC Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoran Andric, MD</last_name>
      <phone>+381 214 805 277</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of Serbia, Pulmonology Clinic</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milica Kontic, MD</last_name>
      <phone>+381 63 554 963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Clinic for Pulmonary Diseases</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milan Rancic, MD</last_name>
      <phone>+381 18 200 424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Pulmonary Diseases of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bojan Zaric, MD</last_name>
      <phone>+381 214 805 224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Ponce, MD</last_name>
      <phone>+34 91 469 2313</phone>
      <email>sponceaix@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

